1404P Update results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial

Abstract

Conclusions: Toripalimab in combination with paclitaxel as second-line therapy for advanced GC showed tolerant toxicity and preliminary clinical efficacy. The conclusion should be validated in more pts consecutively.Clinical trial identification: NCT04563975.